Updated: Jun 25, 2025
CARDIFF-BY-THE-SEA, Calif., April 23, 2025 /PRNewswire/ -- Field Medical Inc., a leader in cardiac pulsed field ablation (PFA) technology, announced today its FieldForce™ Ablation System will be featured in eight scientific presentations at the 46th annual Heart Rhythm Society (HRS) meeting, April 24–27, in San Diego, Calif.
Read the full press release here.
Updated: Jun 25, 2025
CARDIFF-BY-THE-SEA, Calif., April 21, 2025 /PRNewswire/ -- Field Medical Inc., a pioneer in cardiac pulsed field ablation (PFA) technology, today announced the successful closing of $40 million in Series A financing. The round includes $20 million in new capital and the conversion of $20 million in seed-round debt. Participants include several leading strategics, venture capital firms and family offices, with multiple seed investors reinvesting – underscoring strong confidence in the company's initial focus on ventricular tachycardia (VT) and the broader versatility of its technology.
Read the full press release here.
Field Medical's FieldForce™ Ablation System, the first and only contact force pulsed field ablation (PFA) system, has received FDA TAP Pilot acceptance and Breakthrough Device Designation for its revolutionary approach to treating ventricular tachycardia (VT). This critical advancement is set to redefine care for patients at risk of sudden cardiac death from VT.
Read the full press release here.